Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies - Centre de Recherche en Transplantation et Immunologie
Article Dans Une Revue International Journal of Molecular Sciences Année : 2021

Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies

Résumé

Myeloid regulatory cell-based therapy has been shown to be a promising cell-based medicinal approach in organ transplantation and for the treatment of autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis, Crohn’s disease and multiple sclerosis. Dendritic cells (DCs) are the most efficient antigen-presenting cells and can naturally acquire tolerogenic properties through a variety of differentiation signals and stimuli. Several subtypes of DCs have been generated using additional agents, including vitamin D3, rapamycin and dexamethasone, or immunosuppressive cytokines, such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). These cells have been extensively studied in animals and humans to develop clinical-grade tolerogenic (tol)DCs. Regulatory macrophages (Mregs) are another type of protective myeloid cell that provide a tolerogenic environment, and have mainly been studied within the context of research on organ transplantation. This review aims to thoroughly describe the ex vivo generation of tolDCs and Mregs, their mechanism of action, as well as their therapeutic application and assessment in human clinical trials.
Fichier principal
Vignette du fichier
ijms-22-07970-v3.pdf (2 Mo) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-04699073 , version 1 (16-09-2024)

Licence

Identifiants

Citer

Maaike Suuring, Aurélie Moreau. Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies. International Journal of Molecular Sciences, 2021, 22 (15), pp.7970. ⟨10.3390/ijms22157970⟩. ⟨hal-04699073⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More